[go: up one dir, main page]

IL201842A0 - Novel peptide inhibitors of hepatitis c virus replication - Google Patents

Novel peptide inhibitors of hepatitis c virus replication

Info

Publication number
IL201842A0
IL201842A0 IL201842A IL20184209A IL201842A0 IL 201842 A0 IL201842 A0 IL 201842A0 IL 201842 A IL201842 A IL 201842A IL 20184209 A IL20184209 A IL 20184209A IL 201842 A0 IL201842 A0 IL 201842A0
Authority
IL
Israel
Prior art keywords
hepatitis
virus replication
peptide inhibitors
novel peptide
novel
Prior art date
Application number
IL201842A
Original Assignee
Intermune Inc
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39743068&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL201842(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Intermune Inc, Array Biopharma Inc filed Critical Intermune Inc
Publication of IL201842A0 publication Critical patent/IL201842A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
IL201842A 2007-05-10 2009-10-29 Novel peptide inhibitors of hepatitis c virus replication IL201842A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91730007P 2007-05-10 2007-05-10
US2304108P 2008-01-23 2008-01-23
PCT/US2008/063304 WO2008141227A1 (en) 2007-05-10 2008-05-09 Novel peptide inhibitors of hepatitis c virus replication

Publications (1)

Publication Number Publication Date
IL201842A0 true IL201842A0 (en) 2010-06-16

Family

ID=39743068

Family Applications (1)

Application Number Title Priority Date Filing Date
IL201842A IL201842A0 (en) 2007-05-10 2009-10-29 Novel peptide inhibitors of hepatitis c virus replication

Country Status (22)

Country Link
US (1) US7932277B2 (en)
EP (1) EP2185524A1 (en)
JP (1) JP2010526834A (en)
KR (1) KR20100027134A (en)
CN (1) CN101679277A (en)
AP (1) AP2009005057A0 (en)
AR (1) AR066528A1 (en)
AU (1) AU2008251425A1 (en)
BR (1) BRPI0811447A2 (en)
CA (1) CA2686546A1 (en)
CL (1) CL2008001381A1 (en)
CO (1) CO6241100A2 (en)
EA (1) EA200971041A1 (en)
EC (1) ECSP099792A (en)
IL (1) IL201842A0 (en)
MA (1) MA31497B1 (en)
MX (1) MX2009012093A (en)
NI (1) NI200900205A (en)
TN (1) TN2009000481A1 (en)
TW (1) TW200902520A (en)
WO (1) WO2008141227A1 (en)
ZA (1) ZA200907858B (en)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003007697A (en) * 2001-06-21 2003-01-10 Hitachi Kokusai Electric Inc Semiconductor device manufacturing method, substrate processing method and substrate processing apparatus
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
US7491794B2 (en) * 2003-10-14 2009-02-17 Intermune, Inc. Macrocyclic compounds as inhibitors of viral replication
NZ565059A (en) * 2005-07-25 2011-08-26 Intermune Inc Novel macrocyclic inhibitors of hepatitus C virus replication
BRPI0617274A2 (en) * 2005-10-11 2011-07-19 Intermune Inc compounds and methods for inhibiting hepatitis c viral replication
AU2008251425A1 (en) 2007-05-10 2008-11-20 Array Biopharma, Inc. Novel peptide inhibitors of hepatitis C virus replication
CA2720729A1 (en) 2008-04-15 2009-11-26 Intermune, Inc. Novel macrocyclic inhibitors of hepatitis c virus replication
US8163921B2 (en) * 2008-04-16 2012-04-24 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20090285774A1 (en) * 2008-05-15 2009-11-19 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US8207341B2 (en) 2008-09-04 2012-06-26 Bristol-Myers Squibb Company Process or synthesizing substituted isoquinolines
UY32099A (en) 2008-09-11 2010-04-30 Enanta Pharm Inc HEPATITIS C SERINA PROTEASAS MACROCYCLIC INHIBITORS
EP2358736A1 (en) * 2008-10-15 2011-08-24 Intermune, Inc. Therapeutic antiviral peptides
AR075584A1 (en) 2009-02-27 2011-04-20 Intermune Inc THERAPEUTIC COMPOSITIONS THAT INCLUDE beta-D-2'-DESOXI-2'-FLUORO-2'-C-METHYLYCTIDINE AND A CARDIEX ISOINDOL ACID DERIVATIVE AND ITS USES. COMPOUND.
WO2010118078A1 (en) 2009-04-08 2010-10-14 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors
US8232246B2 (en) 2009-06-30 2012-07-31 Abbott Laboratories Anti-viral compounds
WO2011017389A1 (en) 2009-08-05 2011-02-10 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors useful against viral infections, particularly hcv
EP2483290A4 (en) * 2009-09-28 2013-05-01 Intermune Inc Cyclic peptide inhibitors of hepatitis c virus replication
WO2012047764A1 (en) * 2010-10-04 2012-04-12 Intermune, Inc. Therapeutic antiviral peptides
EP2658859A4 (en) 2010-12-30 2014-07-30 Enanta Pharm Inc Macrocyclic hepatitis c serine protease inhibitors
MX2013007698A (en) 2010-12-30 2013-08-15 Abbvie Inc Phenanthridine macrocyclic hepatitis c serine protease inhibitors.
US9353100B2 (en) 2011-02-10 2016-05-31 Idenix Pharmaceuticals Llc Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
ES2529143B1 (en) 2011-10-21 2015-10-26 Abbvie Inc. COMBINATION OF AT LEAST TWO DIRECT ACTION ANTIVIRAL AGENTS, RIBAVIRINE BUT NOT INTERFERONED FOR THE USE OF HCV TREATMENT
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
CH707030B1 (en) 2011-10-21 2015-03-13 Abbvie Inc Combination treatment of DAAs for use in the treatment of HCV
UA119315C2 (en) 2012-07-03 2019-06-10 Гіліад Фармассет Елелсі HEPATITIS VIRUS INHIBITORS C
WO2014062196A1 (en) 2012-10-19 2014-04-24 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9334279B2 (en) 2012-11-02 2016-05-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2914613B1 (en) 2012-11-02 2017-11-22 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2914614B1 (en) 2012-11-05 2017-08-16 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
CN105164148A (en) 2013-03-07 2015-12-16 百时美施贵宝公司 Hepatitis c virus inhibitors
JP6511432B2 (en) 2013-03-15 2019-05-15 ギリアード サイエンシーズ， インコーポレイテッド Macrocyclic bicyclic inhibitors of hepatitis C virus
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
EP3448392A4 (en) 2016-04-28 2020-01-15 Emory University ALCYNE-CONTAINING NUCLEOTIDES AND NUCLEOSIDES THERAPEUTIC COMPOSITIONS AND USES THEREOF
EP3472149B1 (en) 2016-06-21 2023-08-30 Orion Ophthalmology LLC Heterocyclic prolinamide derivatives
WO2017222914A1 (en) 2016-06-21 2017-12-28 Inception 4, Inc. Carbocyclic prolinamide derivatives
IL309732A (en) 2021-07-09 2024-02-01 Aligos Therapeutics Inc Anti-viral compounds
WO2023043816A1 (en) 2021-09-17 2023-03-23 Aligos Therapeutics, Inc. Anti-viral compounds for treating coronavirus, picornavirus, and norovirus infections

Family Cites Families (201)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3547119A (en) 1967-12-08 1970-12-15 Baxter Laboratories Inc Catheter assembly
US4211771A (en) 1971-06-01 1980-07-08 Robins Ronald K Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide
US4311137A (en) 1980-04-30 1982-01-19 Sherwood Medical Industries Inc. Infusion device
US4531937A (en) 1983-01-24 1985-07-30 Pacesetter Systems, Inc. Introducer catheter apparatus and method of use
US4511937A (en) * 1983-03-14 1985-04-16 Sony Corporation Inertial tape positioning method and apparatus
HU196607B (en) 1985-05-15 1988-12-28 Wellcome Found Process for producing dideoxy-nucleosides and pharmaceutics comprising such compounds
US4755173A (en) 1986-02-25 1988-07-05 Pacesetter Infusion, Ltd. Soft cannula subcutaneous injection set
GB8815265D0 (en) 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
US5552558A (en) 1989-05-23 1996-09-03 Abbott Laboratories Retroviral protease inhibiting compounds
US5354866A (en) 1989-05-23 1994-10-11 Abbott Laboratories Retroviral protease inhibiting compounds
US5232928A (en) 1989-07-25 1993-08-03 Boehringer Ingelheim Pharmaceuticals, Inc. Tetrahydroisoquinoline amides
US5310562A (en) 1989-11-22 1994-05-10 Margolin Solomon B Composition and method for reparation and prevention of fibrotic lesions
US5716632A (en) 1989-11-22 1998-02-10 Margolin; Solomon B. Compositions and methods for reparation and prevention of fibrotic lesions
US5518729A (en) 1989-11-22 1996-05-21 Margolin; Solomon B. Compositions and methods for reparation and prevention of fibrotic lesions
US5350562A (en) * 1991-04-09 1994-09-27 Anthony Frank H Method and apparatus for sterilization and separation of plastic and non-plastic medical wastes
KR100187613B1 (en) 1992-12-29 1999-06-01 스티븐 에프. 웨인스톡 Retroviral Protease Inhibiting Compounds, Methods for Making the Same, and Pharmaceutical Compositions Containing the Same
US5545143A (en) 1993-01-21 1996-08-13 T. S. I. Medical Device for subcutaneous medication delivery
US5624949A (en) 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors
US6693072B2 (en) 1994-06-02 2004-02-17 Aventis Pharmaceuticals Inc. Elastase inhibitors
US5847135A (en) 1994-06-17 1998-12-08 Vertex Pharmaceuticals, Incorporated Inhibitors of interleukin-1β converting enzyme
US5756466A (en) 1994-06-17 1998-05-26 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
US6090822A (en) 1995-03-03 2000-07-18 Margolin; Solomon B. Treatment of cytokine growth factor caused disorders
US6232333B1 (en) 1996-11-21 2001-05-15 Abbott Laboratories Pharmaceutical composition
US5968895A (en) 1996-12-11 1999-10-19 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
US6767991B1 (en) 1997-08-11 2004-07-27 Boehringer Ingelheim (Canada) Ltd. Hepatitis C inhibitor peptides
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
US6277830B1 (en) 1998-10-16 2001-08-21 Schering Corporation 5′-amino acid esters of ribavirin and the use of same to treat hepatitis C with interferon
US7157430B2 (en) 1998-10-22 2007-01-02 Idun Pharmaceuticals, Inc. (Substituted)acyl dipeptidyl inhibitors of the ICE/CED-3 family of cysteine proteases
US6608027B1 (en) 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
UA74546C2 (en) 1999-04-06 2006-01-16 Boehringer Ingelheim Ca Ltd Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
US6232180B1 (en) * 1999-07-02 2001-05-15 Taiwan Semiconductor Manufacturing Corporation Split gate flash memory cell
US6232928B1 (en) * 2000-02-03 2001-05-15 Ems Technologies, Inc. Antenna mounting bracket assembly
JP4806154B2 (en) 2000-04-03 2011-11-02 バーテックス ファーマシューティカルズ インコーポレイテッド Inhibitors of serine proteases, especially hepatitis C virus NS3 protease
MXPA02009920A (en) 2000-04-05 2003-03-27 Schering Corp Macrocyclic ns3 serine protease inhibitors of hepatitis c virus comprising n cyclic p2 moieties.
HUP0302957A2 (en) 2000-04-19 2003-12-29 Schering Corporation Macrocyclic ns3-serine protease inhibitors of hepatitis c virus comprising alkyl and aryl alanine p2 moieties
ES2341534T3 (en) 2000-07-21 2010-06-22 Schering Corporation PEPTIDES AS INHIBITORS OF THE SERINA PROTEASA NS3 OF THE VIRUS OF HEPATITIS C.
US7244721B2 (en) 2000-07-21 2007-07-17 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
PE20020707A1 (en) * 2000-11-20 2002-08-11 Bristol Myers Squibb Co TRIPEPTIDE COMPOUNDS AS INHIBITORS OF THE PROTEASE NS3 OF THE HEPATITIS C VIRUS
FR2821446B1 (en) * 2001-02-26 2003-06-13 Eads Airbus Sa AIRCRAFT DIALOGUE DEVICE FOR DIALOGUE WITH AN AIRCRAFT SYSTEM
EP1408986B1 (en) 2001-05-08 2008-09-24 Yale University Proteomimetic compounds and methods
JP4455056B2 (en) 2001-07-11 2010-04-21 バーテックス ファーマシューティカルズ インコーポレイテッド Cross-linked bicyclic serine protease inhibitor
US6867185B2 (en) 2001-12-20 2005-03-15 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
US7119072B2 (en) 2002-01-30 2006-10-10 Boehringer Ingelheim (Canada) Ltd. Macrocyclic peptides active against the hepatitis C virus
CA2369711A1 (en) 2002-01-30 2003-07-30 Boehringer Ingelheim (Canada) Ltd. Macrocyclic peptides active against the hepatitis c virus
US7091184B2 (en) 2002-02-01 2006-08-15 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
CA2369970A1 (en) 2002-02-01 2003-08-01 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor tri-peptides
CA2370400A1 (en) * 2002-02-01 2003-08-01 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor tri-peptides
US6642204B2 (en) 2002-02-01 2003-11-04 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
CA2370396A1 (en) * 2002-02-01 2003-08-01 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor tri-peptides
US6828301B2 (en) 2002-02-07 2004-12-07 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for hepatitis C viral protease inhibitors
RU2004133044A (en) 2002-04-11 2006-01-27 Вертекс Фармасьютикалз Инкорпорейтед (Us) SERINE PROTEASES INHIBITORS, IN PARTICULAR, NS3-NS4A HCV PROTEASES
ATE481106T1 (en) 2002-05-20 2010-10-15 Bristol Myers Squibb Co HETEROCYCLIC SULFONAMIDE HEPATITIS C VIRUS INHIBITORS
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
US20060199773A1 (en) 2002-05-20 2006-09-07 Sausker Justin B Crystalline forms of (1R,2S)-N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(6-methoxy-1-isoquinolinyl)oxy]-L-prolyl-1-amino-N-(cyclopropylsulfonyl)-2-ethenyl-cyclopropanecarboxamide, monopotassium salt
AU2003301959A1 (en) 2002-05-20 2004-06-03 Bristol-Myers Squibb Company Substituted cycloalkyl p1' hepatitis c virus inhibitors
ES2361011T3 (en) 2002-05-20 2011-06-13 Bristol-Myers Squibb Company HEPATITIS VIRUS INHIBITORS C.
US20040033959A1 (en) 2002-07-19 2004-02-19 Boehringer Ingelheim Pharmaceuticals, Inc. Pharmaceutical compositions for hepatitis C viral protease inhibitors
US6848802B2 (en) * 2002-09-18 2005-02-01 Chung-Yang M. Chen Computer light with extensible electric conductive wire
US20040138109A1 (en) 2002-09-30 2004-07-15 Boehringer Ingelheim Pharmaceuticals, Inc. Potent inhibitor of HCV serine protease
PL199412B1 (en) 2002-10-15 2008-09-30 Boehringer Ingelheim Int Ruthenium new complexes as (pre) catalytic agents of permutation reaction, new derivatives of 2-alkoxy-5-nitrostyrene as intermediate compounds and method of their receiving
US20050075279A1 (en) 2002-10-25 2005-04-07 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis C virus
US7206600B2 (en) * 2002-12-26 2007-04-17 Intel Corporation Method and apparatus of antenna detection and authentication
US7601709B2 (en) 2003-02-07 2009-10-13 Enanta Pharmaceuticals, Inc. Macrocyclic hepatitis C serine protease inhibitors
US20040180815A1 (en) 2003-03-07 2004-09-16 Suanne Nakajima Pyridazinonyl macrocyclic hepatitis C serine protease inhibitors
JP4550824B2 (en) 2003-03-05 2010-09-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Hepatitis C inhibitory compound
UY28240A1 (en) 2003-03-27 2004-11-08 Boehringer Ingelheim Pharma CRYSTAL PHASES OF A POWERFUL HCV INHIBITOR
WO2004093915A1 (en) 2003-04-02 2004-11-04 Boehringer Ingelheim International, Gmbh Pharmaceutical compositions for hepatitis c viral protease inhibitors
CA2522205A1 (en) 2003-04-10 2004-10-28 Boehringer Ingelheim International Gmbh Process for preparing macrocyclic compounds
JP2007523833A (en) 2003-04-10 2007-08-23 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Process for producing macrocyclic compounds by ruthenium complex-catalyzed metathesis reaction
JP4733023B2 (en) 2003-04-16 2011-07-27 ブリストル−マイヤーズ スクイブ カンパニー Macrocyclic isoquinoline peptide inhibitor of hepatitis C virus
US7176208B2 (en) 2003-04-18 2007-02-13 Enanta Pharmaceuticals, Inc. Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors
DK1628685T3 (en) 2003-04-25 2011-03-21 Gilead Sciences Inc Antiviral phosphonate analogues
WO2004099134A2 (en) 2003-05-05 2004-11-18 Prosidion Ltd. Glutaminyl based dp iv-inhibitors
US7273851B2 (en) 2003-06-05 2007-09-25 Enanta Pharmaceuticals, Inc. Tri-peptide hepatitis C serine protease inhibitors
US7125845B2 (en) 2003-07-03 2006-10-24 Enanta Pharmaceuticals, Inc. Aza-peptide macrocyclic hepatitis C serine protease inhibitors
AU2004257277B2 (en) 2003-07-10 2011-03-31 Achillion Pharmaceuticals, Inc. Substituted arylthiourea derivatives useful as inhibitors of viral replication
CA2536570A1 (en) * 2003-08-26 2005-03-10 Schering Corporation Novel peptidomimetic ns3-serine protease inhibitors of hepatitis c virus
MY148123A (en) 2003-09-05 2013-02-28 Vertex Pharma Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
US20050119189A1 (en) 2003-09-18 2005-06-02 Cottrell Kevin M. Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
MXPA06003141A (en) 2003-09-22 2006-06-05 Boehringer Ingelheim Int Macrocyclic peptides active against the hepatitis c virus.
RU2006115558A (en) 2003-10-10 2007-11-20 Вертекс Фармасьютикалз Инкорпорейтед (Us) SERINE PROTEASES INHIBITORS, ESPECIALLY HCV NS3-NS4A PROTEASES
US7365092B2 (en) 2003-10-10 2008-04-29 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
TW201245229A (en) 2003-10-14 2012-11-16 Hoffmann La Roche Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of HCV replication
US7491794B2 (en) 2003-10-14 2009-02-17 Intermune, Inc. Macrocyclic compounds as inhibitors of viral replication
EP1678202B1 (en) 2003-10-27 2012-06-13 Vertex Pharmaceuticals Incorporated Hcv ns3-ns4a protease resistance mutants
US7132504B2 (en) 2003-11-12 2006-11-07 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7309708B2 (en) * 2003-11-20 2007-12-18 Birstol-Myers Squibb Company Hepatitis C virus inhibitors
JP2007516239A (en) 2003-11-20 2007-06-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Method for removing transition metals, particularly from metathesis products
US7135462B2 (en) 2003-11-20 2006-11-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
DE602004019973D1 (en) 2003-12-08 2009-04-23 Boehringer Ingelheim Int SEPARATION OF RUTHENIUM BY-PRODUCTS BY TREATMENT WITH SUPERCRITICAL LIQUIDS
CA2549167A1 (en) 2003-12-11 2005-06-30 Schering Corporation Inhibitors of hepatitis c virus ns3/ns4a serine protease
EP1730167B1 (en) 2004-01-21 2011-01-12 Boehringer Ingelheim International GmbH Macrocyclic peptides active against the hepatitis c virus
CA2544886C (en) 2004-01-28 2012-12-04 Boehringer Ingelheim International Gmbh Method of removing transition metals from reaction solutions comprising transition metal byproducts
RS51243B (en) 2004-01-30 2010-12-31 Medivir Ab. NS-3 SERINA HCV PROTEAZE INHIBITORS
JP2008505849A (en) 2004-02-04 2008-02-28 バーテックス　ファーマシューティカルズ　インコーポレイテッド Inhibitors of serine proteases, particularly HCV, NS3-NS4A protease
ATE514691T1 (en) 2004-02-27 2011-07-15 Schering Corp NEW KETOAMIDES WITH CYCLIC P4 AS INHIBITORS OF THE NS3 SERINE PROTEASE OF HEPATITIS C VIRUS
AU2005222056A1 (en) 2004-02-27 2005-09-22 Schering Corporation Novel compounds as inhibitors of hepatitis C virus NS3 serine protease
AU2005219859A1 (en) 2004-02-27 2005-09-15 Schering Corporation Inhibitors of hepatitis C virus NS3 protease
ES2328589T3 (en) 2004-02-27 2009-11-16 Schering Corporation PROLIN 3.4 COMPOUNDS (CYCLOPENTIL) FUSED AS INHIBITORS OF THE SERINE PROTEASE NS3 OF THE HEPATITIS VIRUS C.
DE602005019700D1 (en) 2004-03-15 2010-04-15 Boehringer Ingelheim Int E, SUITABLE FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTIONS
EP1773868B1 (en) 2004-05-20 2009-07-15 Schering Corporation Substituted prolines as inhibitors of hepatitis c virus ns3 serine protease
JP5156374B2 (en) 2004-05-25 2013-03-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Method for preparing acyclic HCV protease inhibitor
US7939538B2 (en) 2004-06-28 2011-05-10 Amgen Inc. Compounds, compositions and methods for prevention and treatment of inflammatory and immunoregulatory disorders and diseases
MX2007000584A (en) 2004-07-16 2007-06-25 Gilead Sciences Inc Antiviral compounds.
UY29016A1 (en) 2004-07-20 2006-02-24 Boehringer Ingelheim Int ANALOGS OF INHIBITING DIPEPTIDES OF HEPATITIS C
EP1771454B1 (en) 2004-07-20 2011-06-15 Boehringer Ingelheim International GmbH Hepatitis c inhibitor peptide analogs
CA2577812A1 (en) 2004-08-27 2006-03-09 Schering Corporation Acylsulfonamide compounds as inhibitors of hepatitis c virus ns3 serine protease
WO2006033878A1 (en) 2004-09-17 2006-03-30 Boehringer Ingelheim International, Gmbh Process for preparing macrocyclic hcv protease inhibitors
CA2578428A1 (en) 2004-09-17 2006-03-30 Boehringer Ingelheim International Gmbh Ring-closing metathesis process in supercritical fluid
DE102005002336A1 (en) 2005-01-17 2006-07-20 Boehringer Ingelheim Pharma Gmbh & Co. Kg Process for conducting continuous olefin-ring closure metathesis in compressed carbon dioxide
US7323447B2 (en) 2005-02-08 2008-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7524831B2 (en) 2005-03-02 2009-04-28 Schering Corporation Treatments for Flaviviridae virus infection
EP1863941B1 (en) 2005-03-04 2013-05-08 The Rockefeller University Infectious, chimeric hepatitis c virus, methods of producing the same and methods of use thereof
EP2332963A3 (en) 2005-03-08 2011-11-16 Boehringer Ingelheim International Gmbh Process for preparing macrocyclic compounds
US20060252698A1 (en) 2005-04-20 2006-11-09 Malcolm Bruce A Compounds for inhibiting cathepsin activity
JP4705164B2 (en) 2005-05-02 2011-06-22 メルク・シャープ・エンド・ドーム・コーポレイション HCV NS3 protease inhibitor
JP2008545409A (en) 2005-05-26 2008-12-18 シェーリング コーポレイション Interferon-IgG fusion
WO2006130688A2 (en) 2005-06-02 2006-12-07 Schering Corporation Compounds for inhibiting cathepsin activity
WO2006130666A2 (en) 2005-06-02 2006-12-07 Schering Corporation Medicaments and methods combining a hcv protease inhibitor and an akr competitor
WO2006130626A2 (en) 2005-06-02 2006-12-07 Schering Corporation Method for modulating activity of hcv protease through use of a novel hcv protease inhibitor to reduce duration of treatment period
US20070004635A1 (en) 2005-06-02 2007-01-04 Schering Corporation Method of treating interferon non-responders using HCV protease inhibitor
US20070021351A1 (en) 2005-06-02 2007-01-25 Schering Corporation Liver/plasma concentration ratio for dosing hepatitis C virus protease inhibitor
US20060275366A1 (en) 2005-06-02 2006-12-07 Schering Corporation Controlled-release formulation
WO2006130686A2 (en) 2005-06-02 2006-12-07 Schering Corporation Hcv protease inhibitors in combination with food
AU2006252553B2 (en) 2005-06-02 2012-03-29 Merck Sharp & Dohme Corp. Combination of HCV protease inhibitors with a surfactant
US20060276405A1 (en) 2005-06-02 2006-12-07 Schering Corporation Methods for treating hepatitis C
US20060276407A1 (en) 2005-06-02 2006-12-07 Schering Corporation Methods of treating hepatitis C virus
US7608592B2 (en) 2005-06-30 2009-10-27 Virobay, Inc. HCV inhibitors
US7601686B2 (en) 2005-07-11 2009-10-13 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
TWI389908B (en) 2005-07-14 2013-03-21 Gilead Sciences Inc Antiviral compounds
US7470664B2 (en) 2005-07-20 2008-12-30 Merck & Co., Inc. HCV NS3 protease inhibitors
NZ565059A (en) 2005-07-25 2011-08-26 Intermune Inc Novel macrocyclic inhibitors of hepatitus C virus replication
AR055361A1 (en) 2005-07-29 2007-08-22 Medivir Ab MACROCICLIC INHIBITORS OF HEPATITIS C VIRUS
AR055395A1 (en) * 2005-08-26 2007-08-22 Vertex Pharma INHIBITING COMPOUNDS OF THE ACTIVITY OF SERINA PROTEASA NS3-NS4A OF HEPATITIS C VIRUS
BRPI0617274A2 (en) 2005-10-11 2011-07-19 Intermune Inc compounds and methods for inhibiting hepatitis c viral replication
US7772183B2 (en) 2005-10-12 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7741281B2 (en) 2005-11-03 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7705138B2 (en) 2005-11-11 2010-04-27 Vertex Pharmaceuticals Incorporated Hepatitis C virus variants
BRPI0618610A2 (en) 2005-11-16 2011-09-06 Hoffmann La Roche pyrrolidine derivatives as coagulation factor xa inhibitors
PE20080197A1 (en) 2006-02-09 2008-04-11 Schering Corp COMBINATIONS INVOLVING THE HCV PROTEASE INHIBITOR (S), AND TREATMENT METHODS RELATED TO THE SAME (S)
JP2009530382A (en) 2006-03-23 2009-08-27 シェーリング コーポレイション Combinations of HCV protease inhibitors and CYP3A4 inhibitors and related treatment methods
EP2007789B1 (en) * 2006-04-11 2015-05-20 Novartis AG Spirocyclic HCV/HIV inhibitors and their uses
US7728148B2 (en) 2006-06-06 2010-06-01 Enanta Pharmaceuticals, Inc. Acyclic oximyl hepatitis C protease inhibitors
US9526769B2 (en) 2006-06-06 2016-12-27 Enanta Pharmaceuticals, Inc. Macrocylic oximyl hepatitis C protease inhibitors
US20080187516A1 (en) 2006-06-06 2008-08-07 Ying Sun Acyclic oximyl hepatitis c protease inhibitors
WO2007145894A2 (en) 2006-06-08 2007-12-21 Merck & Co., Inc. A rapid method to determine inhibitor sensitivity of ns3/4a protease sequences
PE20080992A1 (en) 2006-06-26 2008-08-06 Enanta Pharm Inc QUINOXALINYL MACROCYCLIC SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS
RU2008152171A (en) 2006-07-05 2010-08-10 Интермьюн, Инк. (Us) NEW HEPATITIS C VIRAL REPLICATION INHIBITORS
EP2049474B1 (en) 2006-07-11 2015-11-04 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
PT2041156E (en) 2006-07-13 2014-02-21 Achillion Pharmaceuticals Inc 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication
US20090035267A1 (en) 2007-07-31 2009-02-05 Moore Joel D Acyclic, pyridazinone-derived hepatitis c serine protease inhibitors
CA2656816A1 (en) 2006-08-04 2008-02-14 Enanta Pharmaceuticals, Inc. Tetrazolyl macrocyclic hepatitis c serine protease inhibitors
US7635683B2 (en) 2006-08-04 2009-12-22 Enanta Pharmaceuticals, Inc. Quinoxalinyl tripeptide hepatitis C virus inhibitors
US7718612B2 (en) 2007-08-02 2010-05-18 Enanta Pharmaceuticals, Inc. Pyridazinonyl macrocyclic hepatitis C serine protease inhibitors
US20090098085A1 (en) 2006-08-11 2009-04-16 Ying Sun Tetrazolyl acyclic hepatitis c serine protease inhibitors
US7605126B2 (en) 2006-08-11 2009-10-20 Enanta Pharmaceuticals, Inc. Acylaminoheteroaryl hepatitis C virus protease inhibitors
US7687459B2 (en) 2006-08-11 2010-03-30 Enanta Pharmaceuticals, Inc. Arylalkoxyl hepatitis C virus protease inhibitors
US20080038225A1 (en) 2006-08-11 2008-02-14 Ying Sun Triazolyl acyclic hepatitis c serine protease inhibitors
US20090035268A1 (en) 2007-08-01 2009-02-05 Ying Sun Tetrazolyl acyclic hepatitis c serine protease inhibitors
US7662779B2 (en) 2006-08-11 2010-02-16 Enanta Pharmaceuticals, Inc. Triazolyl macrocyclic hepatitis C serine protease inhibitors
US20080107623A1 (en) 2006-11-01 2008-05-08 Bristol-Myers Squibb Company Inhibitors of Hepatitis C Virus
US8343477B2 (en) 2006-11-01 2013-01-01 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
US20080107625A1 (en) 2006-11-01 2008-05-08 Bristol-Myers Squibb Company Inhibitors of Hepatitis C Virus
US7772180B2 (en) 2006-11-09 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
AU2007321182B2 (en) 2006-11-17 2013-11-14 Tibotec Pharmaceuticals Ltd. Macrocyclic inhibitors of hepatitis C virus
US7951789B2 (en) 2006-12-28 2011-05-31 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
US20100087382A1 (en) 2007-02-16 2010-04-08 Boehringer Ingelheim International Gmbh Inhibitors of Hepatitis C NS3 Protease
MX2009010205A (en) 2007-03-23 2009-10-19 Schering Corp P1-nonepimerizable ketoamide inhibitors of hcv ns3 protease.
CA2684169C (en) 2007-04-12 2012-06-19 Joyant Pharmaceuticals, Inc. Smac mimetic dimers and trimers useful as anti-cancer agents
WO2008128921A1 (en) 2007-04-24 2008-10-30 F. Hoffmann-La Roche Ag Process for hcv protease inhibitor intermediate
US20080267917A1 (en) 2007-04-26 2008-10-30 Deqiang Niu N-functionalized amides as hepatitis c serine protease inhibitors
WO2008134397A1 (en) 2007-04-26 2008-11-06 Enanta Pharmaceuticals, Inc. Aza-tripeptide hepatitis c serine protease inhibitors
US7910587B2 (en) 2007-04-26 2011-03-22 Enanta Pharmaceuticals, Inc. Quinoxalinyl dipeptide hepatitis C virus inhibitors
US8377872B2 (en) 2007-04-26 2013-02-19 Enanta Pharmaceuticals, Inc. Cyclic P3 tripeptide hepatitis C serine protease inhibitors
US20080279821A1 (en) 2007-04-26 2008-11-13 Deqiang Niu Arylpiperidinyl and arylpyrrolidinyl macrocyclic hepatitis c serine protease inhibitors
WO2008134395A1 (en) 2007-04-26 2008-11-06 Enanta Pharmaceuticals, Inc. Aza-peptide macrocyclic hepatitis c serine protease inhibitors
US20090123423A1 (en) 2007-04-26 2009-05-14 Yonghua Gai Hydroxyamic analogs as hepatitis c virus serine protease inhibitor
US20080317712A1 (en) 2007-04-26 2008-12-25 Deqiang Niu Arylpiperidinyl and arylpyrrolidinyl tripeptide hepatitis c serine protease inhibitors
US7906513B2 (en) 2007-04-26 2011-03-15 Enanta Pharmaceuticals, Inc. Hydrazide-containing hepatitis C serine protease inhibitors
US20080274082A1 (en) 2007-04-26 2008-11-06 Yonghua Gai Oximyl hydroxyamic analogs as hepatitis c virus protease inhibitor
AP2009005053A0 (en) 2007-05-03 2009-12-31 Intermune Inc Novel macrocyclic inhibitors of hepatitis c virus replication
AU2008251425A1 (en) 2007-05-10 2008-11-20 Array Biopharma, Inc. Novel peptide inhibitors of hepatitis C virus replication
US20090005387A1 (en) 2007-06-26 2009-01-01 Deqiang Niu Quinoxalinyl macrocyclic hepatitis c virus serine protease inhibitors
WO2009003009A1 (en) 2007-06-26 2008-12-31 Enanta Pharmaceuticals, Inc. Substituted pyrrolidine as anti-infectives
US20090047252A1 (en) 2007-06-29 2009-02-19 Gilead Sciences, Inc. Antiviral compounds
WO2009014730A1 (en) 2007-07-26 2009-01-29 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors
US20090053175A1 (en) 2007-08-24 2009-02-26 Yat Sun Or Substitute pyrrolidine derivatives
US20090060874A1 (en) 2007-09-05 2009-03-05 Yao-Ling Qiu Bicyclic pyrrolidine derivatives
JP2010540549A (en) 2007-09-24 2010-12-24 アキリオン ファーマシューティカルズ，インコーポレーテッド Urea-containing peptides as viral replication inhibitors
US20090082366A1 (en) 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched telaprevir
US20090111757A1 (en) 2007-10-25 2009-04-30 Taigen Biotechnology Co., Ltd. Hcv protease inhibitors
US8383583B2 (en) 2007-10-26 2013-02-26 Enanta Pharmaceuticals, Inc. Macrocyclic, pyridazinone-containing hepatitis C serine protease inhibitors
US8426360B2 (en) 2007-11-13 2013-04-23 Enanta Pharmaceuticals, Inc. Carbocyclic oxime hepatitis C virus serine protease inhibitors
WO2009076166A2 (en) 2007-12-05 2009-06-18 Enanta Pharmaceuticals, Inc. Oximyl hcv serine protease inhibitors
WO2009085978A1 (en) 2007-12-20 2009-07-09 Enanta Pharceuticals, Inc. Bridged carbocyclic oxime hepatitis c virus serine protease inhibitors
US8003659B2 (en) 2008-02-04 2011-08-23 Indenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors
EP2237793A4 (en) 2008-02-07 2013-07-31 Virobay Inc Inhibitors of cathepsin b
CA2720729A1 (en) 2008-04-15 2009-11-26 Intermune, Inc. Novel macrocyclic inhibitors of hepatitis c virus replication
WO2009134987A1 (en) 2008-04-30 2009-11-05 Enanta Pharmaceuticals, Inc. Difluoromethyl-containing macrocyclic compounds as hepatitis c virus inhibitors
WO2009137432A1 (en) 2008-05-09 2009-11-12 Boehringer Ingelheim International Gmbh A method for preparing macrocycles
EP2358736A1 (en) 2008-10-15 2011-08-24 Intermune, Inc. Therapeutic antiviral peptides

Also Published As

Publication number Publication date
AP2009005057A0 (en) 2009-12-31
AU2008251425A1 (en) 2008-11-20
WO2008141227A1 (en) 2008-11-20
KR20100027134A (en) 2010-03-10
MA31497B1 (en) 2010-07-01
US7932277B2 (en) 2011-04-26
TN2009000481A1 (en) 2011-03-31
EP2185524A1 (en) 2010-05-19
EA200971041A1 (en) 2010-08-30
CL2008001381A1 (en) 2008-11-03
BRPI0811447A2 (en) 2014-10-29
CO6241100A2 (en) 2011-01-20
US20090297476A1 (en) 2009-12-03
AR066528A1 (en) 2009-08-26
CN101679277A (en) 2010-03-24
CA2686546A1 (en) 2008-11-20
TW200902520A (en) 2009-01-16
JP2010526834A (en) 2010-08-05
ECSP099792A (en) 2010-01-29
ZA200907858B (en) 2012-04-25
MX2009012093A (en) 2010-01-25
NI200900205A (en) 2010-10-11

Similar Documents

Publication Publication Date Title
IL201842A0 (en) Novel peptide inhibitors of hepatitis c virus replication
IL196256A0 (en) 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication
HUS1700002I1 (en) Inhibitors of hepatitis c virus replication
AP2009005053A0 (en) Novel macrocyclic inhibitors of hepatitis c virus replication
IL218766A0 (en) Cyclic peptide inhibitors of hepatitis c virus replication
IL212786A (en) 4-amino- 4-oxobutanoyl peptides as inhibitors of viral replication
EP2190858A4 (en) Urea-containing peptides as inhibitors of viral replication
IL208529A0 (en) Novel macrocyclic inhibitors of hepatitis c virus replication
HRP20160410T8 (en) Hepatitis c virus inhibitors
ZA200900626B (en) 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication
HK1144232A (en) Novel peptide inhibitors of hepatitis c virus replication
ZA200907644B (en) Novel macrocyclic inhibitors of hepatitis C virus replication
HK1150836A (en) Novel inhibitors of hepatitis c virus replication
HK1128280A (en) Novel inhibitors of hepatitis c virus replication
ZA201104381B (en) New 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication
HUS1500008I1 (en) Hepatitis c virus inhibitors
ZA200903014B (en) Hepatitis C virus inhibitors